Abstract
Cytotoxic T lymphocytes (CTL) are an important component of the host’s immune response to cancer1,2. A number of genes encoding tumor-associated antigens (TAA) and their peptide products which are recognized by CTL in the context of major histocompatibility complex (MHC) class I molecules have recently been identified3,4. Our group has focused on the translation of these new insights into the development and application of novel immunotherapies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kast, W. M. et al. Eradication of adenovirus E 1-induced tumors by E1 A-specific cytotoxic T lymphocytes. Cell 59, 603–607 (1989)
Rosenberg, S.A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: preliminary report. N. Engl. J. Med. 319, 1676–1680 (1988).
Van den Eynde, B., and Brichard, V.G. New tumor antigens recognized by T cells. Current Opinion in Immunology 7, 674–68 (1995).
Boon, T., and Van der Bruggen, P. Human tumor Antigens recognized by T lymphocytes. J. Exp. Med. 183, 725–729 (1996).
Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271–296 (1991).
Sting!, G., and Bergstresser, P. R. Dendritic cells: a major story unfolds. Immunol. Today 16, 330–333 (1995).
Inaba, K., Steinman, R.M., Witmer-Pack, M., Aya, H., Inaba, M., Sudo, T., Wolpe, S., and Schuler, G. Identification of proliferating dendritic cell precursors in mouse blood. J. Exp. Med. 175, 157–1167 (1992).
Inaba, K., Inaba, M., Romani. N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu. S.. and Steinman, R.M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte-macrophage colony-stimulating factor. J. Exp. Med. 176, 693–1702 (1992).
Caux, C., Dezutter-Damboyant, C., Schmitt, D., and Bancherau, J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360, 258–261 (1992).
Romani, N., Gruner, S., Brang, D., Kämpgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Gritsch, P.O., Steinman, R.M. and Schuler. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83–93 (1994).
Szabolcs, P., Moore, M.A. S., and Young, J.W. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-a. J. Immunol. 154, 5851–5861 (1995).
Mayordomo, J.I., Zorina, T., Storkus, W.J., Celuzzi, C.M., Falo, L.D., Kast, W.M., lldstad, S.T., DeLeo, A.B., and Lotze, M.T. Bone marrow-derived dendritic cells pulsed with tumor peptides elicit protective and therapeutic anti-tumor immunity. Nature Med. I. 1297–1302 (1995).
Ossevoort, M.A, Feltkamp, M.C.W., van Veen, K.J.H., Melief, C.J.M., and Kast, W.M. Dendritic cells as carriers for a cytotoxic T lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J. Immunother. 18, 86–94 (1995).
Celluzi, C.M., Mayordomo, J.I., Storkus, W.J., Lotze, M.T., and Falo, L.D. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183, 283–387 (1996).
Paglia, P., Chiodoni, C., Rodolfo, M., and Colombo, M.P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183. 317–322 (1996).
Zitvogel, L., Mayordomo, J.I., Tjandrawan, T., DeLeo, A.B., Clarke, M.R., Lotze, M.T., and Storkus, W.J. Therapy of murine tumors with tumor peptide pulsed dendritic cells: dependence on T cells, B7 costimulation, and Th I -associated cytokines. J. Exp. Med. 183. 87–97 (1996).
Mayordomo, J.I., Loftus, D.J., Sakamoto, H., De Cesare, S.M., Appasamy, P. M., Lotze, M.T., Storkus, W.J., Appella, E., and DeLeo, A.B. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183, 1357–1365 (1996).
Porgador, A., Snyder, D., and Gilboa, E. Induction of antitumor immunity using hone marrow-generated dendritic cells. J. (mmunol. 156, 2918–2926 (1996).
Bakker, A.B.H., Marland, G., de Boer, A.J., Huijbens, J.F., Danen, E.H.J., Adema, G.J., and Figdor, D.G. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 55, 5330–5334 (1995).
van Elsas, A., van der Burg, S.H., van der Minne, C.E., Borghi, M., Mourer, J.S., Melief, C.J.M., and Schrier, P.1. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*020 1 -binding peptides from the Melan-A/MART-1 self antigen. Eur. J. Immunol. 26, 1683–1689 (1996).
Tjandrawan, T., Mäurer, Mchwr(133)1., Castelli, C., Lotze, M.T., and Storkus, W.J. Autologous dendritic cells pulsed with synthetic melanoma peptides elicit specific CTL effector cells in vitro. Manuscript submitted.
Conry, R.M., LoBuglio, Locchel, F., Moore, S.E., Sumerel, L.A., Barlow, D.L., and Curie], D.T. A cardnoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther. 2, 59–66 66 (1995).
D.M., and Wu, T.-C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56,21–26 (1996).
Ciernik,LF., Berzofsky, J.A., and Carbone, D. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol. 156, 2369–2375 (1996).
Wamier, G., Duffour, M.-T., Uyttenhove, C., Gajewski, T., Lurquin, C., Haddada, H., Perricaudet, M., and Boon, T. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int. J. Cancer 67, 303–310 (1996).
Chen, P.W., Wang, M., Bronte, V., Zhai, Y., Rosenberg, S.A., and Restifo, N.P. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156, 224–231 (1996).
Irvine, K.R., Rao, R.B., Rosenberg, S.A., and Restifo, N.P. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 156, 238–245 (1996).
Zhai, Y., Yang, J.C., Kawakami, Y., Spiess, P., Wadsworth, S.C., Cardoza, L.M., Couture, L.A., Smith, A.E., and Rosenberg, S.A. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART I or gp 100 for cancer therapy. J. Immunol. 156, 700–710 (1996).
Yang, N.-S., Burkholder, J.K., Roberts, B., Martinell, B., and McCabe, D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc. Natl. Acad. Sci. USA 87, 9568–9572 (1990).
Burkholder, J.K., Decker, J., and Yang, N.-S. Rapid transgene expression in lymphocyte and macrophage primary cultures after particle bombardment-mediated gene transfer. J. Immunol. Methods 165, 149–156 (1993).
Yang, N.-S., and Sun, W.-H. Gene gun and other non-viral approaches for cancer gene therapy. Nature Med. 1, 481–483 (1995).
Pertmer, T.M., Roberts, T.R., and Haynes, J.R. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J.Virol. 76: 6119–6125 (1996).
Feltkamp, M.C.W., Smis, H.L., Vierboom, M.P.M., Minnaar, R.P., de Jongh, B.M., Drijfhout, J.W., ter Schegget, J., Melief, C.J.M., and Kast, W.M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23, 2242–2249 (1993).
Henderson, R.A., Nimgaonkar, M.T., Watkins, S.C., Robbins, P.D., Ball, E.D., and Finn, O.J. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-I). Cancer Res. 56, 3763–3770 (1996).
Ressing, M.E., Sette, A., Brandt, R.M., Ruppert, J., Wentworth, P.A., Hartmann, M., Oseroff, C., Grey, H.M., Melief, C.J.M., and Kast, W.M. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154: 5934–5943 (1995).
Houbiers, J.G.A., Nijman, H.W., van der Burg, S.H., Drijfhout, J.W., Kenemans, R, man de Velde, C.J.H., Brand, A., Momburg, F., Kast, W.M., and Melief, C.J.M. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23:2072–2077 (1993).
Theobald, M., Biggs, J., Dittmer, D., Levine, A., and Sherman, L. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92: 11993–11997 (1995).
Roth, J.A., Nguyen, D., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., Ferson, D.Z,., Hong,W.K., Komari, R., Lee, J.J., Nesbitt, J.C., Pisters, K.M.W., Putnam, J.B., Schea, R., Shin, D.M., Walsh, D.L., Dolormente, M.M., Han, C.-1., Martin, F.D., Yen, N., Xu, K., Stephens, L.C., McDonnell, T.J., Mukhopadhyay, T., and Cai, T. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 2: 985–991 (1996).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Tüting, T. et al. (1997). Development of Dendritic Cell-Based Genetic Vaccines for Cancer. In: Ricciardi-Castagnoli, P. (eds) Dendritic Cells in Fundamental and Clinical Immunology. Advances in Experimental Medicine and Biology, vol 417. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9966-8_84
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9966-8_84
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9968-2
Online ISBN: 978-1-4757-9966-8
eBook Packages: Springer Book Archive